185 related articles for article (PubMed ID: 19195732)
1. Influence of daily setup measurements and corrections on the estimated delivered dose during IMRT treatment of prostate cancer patients.
van Haaren PM; Bel A; Hofman P; van Vulpen M; Kotte AN; van der Heide UA
Radiother Oncol; 2009 Mar; 90(3):291-8. PubMed ID: 19195732
[TBL] [Abstract][Full Text] [Related]
2. Dosimetric consequences of the application of off-line setup error correction protocols and a hull-volume definition strategy for intensity modulated radiotherapy of prostate cancer.
Baum C; Birkner M; Alber M; Paulsen F; Nüsslin F
Radiother Oncol; 2005 Jul; 76(1):35-42. PubMed ID: 16019092
[TBL] [Abstract][Full Text] [Related]
3. Persistently better treatment planning results of intensity-modulated (IMRT) over conformal radiotherapy (3D-CRT) in prostate cancer patients with significant variation of clinical target volume and/or organs-at-risk.
Fenoglietto P; Laliberte B; Allaw A; Ailleres N; Idri K; Hay MH; Moscardo CL; Gourgou S; Dubois JB; Azria D
Radiother Oncol; 2008 Jul; 88(1):77-87. PubMed ID: 18215434
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the dosimetric impact of non-exclusion of the rectum from the boost PTV in IMRT treatment plans for prostate cancer patients.
Kassim I; Dirkx ML; Heijmen BJ
Radiother Oncol; 2009 Jul; 92(1):62-7. PubMed ID: 19278745
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of supine vs. prone positioning in patients undergoing escalated dose conformal radiotherapy for prostate cancer.
Bayley AJ; Catton CN; Haycocks T; Kelly V; Alasti H; Bristow R; Catton P; Crook J; Gospodarowicz MK; McLean M; Milosevic M; Warde P
Radiother Oncol; 2004 Jan; 70(1):37-44. PubMed ID: 15036850
[TBL] [Abstract][Full Text] [Related]
6. Is ad-hoc plan adaptation based on 2-Step IMRT feasible?
Bratengeier K; Polat B; Gainey M; Grewenig P; Meyer J; Flentje M
Radiother Oncol; 2009 Nov; 93(2):266-72. PubMed ID: 19796833
[TBL] [Abstract][Full Text] [Related]
7. Dosimetric impact and theoretical clinical benefits of fiducial markers for dose escalated prostate cancer radiation treatment.
Gauthier I; Carrier JF; Béliveau-Nadeau D; Fortin B; Taussky D
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(4):1128-33. PubMed ID: 19147306
[TBL] [Abstract][Full Text] [Related]
8. A study of image-guided intensity-modulated radiotherapy with fiducials for localized prostate cancer including pelvic lymph nodes.
Hsu A; Pawlicki T; Luxton G; Hara W; King CR
Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):898-902. PubMed ID: 17459610
[TBL] [Abstract][Full Text] [Related]
9. Strategies for online organ motion correction for intensity-modulated radiotherapy of prostate cancer: prostate, rectum, and bladder dose effects.
Rijkhorst EJ; Lakeman A; Nijkamp J; de Bois J; van Herk M; Lebesque JV; Sonke JJ
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1254-60. PubMed ID: 19857789
[TBL] [Abstract][Full Text] [Related]
10. Boost first, eliminate systematic error, and individualize CTV to PTV margin when treating lymph nodes in high-risk prostate cancer.
Rossi PJ; Schreibmann E; Jani AB; Master VA; Johnstone PA
Radiother Oncol; 2009 Mar; 90(3):353-8. PubMed ID: 18952307
[TBL] [Abstract][Full Text] [Related]
11. Application of a novel dose-uncertainty model for dose-uncertainty analysis in prostate intensity-modulated radiotherapy.
Jin H; Palta JR; Kim YH; Kim S
Int J Radiat Oncol Biol Phys; 2010 Nov; 78(3):920-8. PubMed ID: 20584579
[TBL] [Abstract][Full Text] [Related]
12. Analysis of fiducial marker-based position verification in the external beam radiotherapy of patients with prostate cancer.
van der Heide UA; Kotte AN; Dehnad H; Hofman P; Lagenijk JJ; van Vulpen M
Radiother Oncol; 2007 Jan; 82(1):38-45. PubMed ID: 17141903
[TBL] [Abstract][Full Text] [Related]
13. Dose-volume comparison of proton therapy and intensity-modulated radiotherapy for prostate cancer.
Vargas C; Fryer A; Mahajan C; Indelicato D; Horne D; Chellini A; McKenzie C; Lawlor P; Henderson R; Li Z; Lin L; Olivier K; Keole S
Int J Radiat Oncol Biol Phys; 2008 Mar; 70(3):744-51. PubMed ID: 17904306
[TBL] [Abstract][Full Text] [Related]
14. Does intensity modulated radiation therapy (IMRT) prevent additional toxicity of treating the pelvic lymph nodes compared to treatment of the prostate only?
Guckenberger M; Baier K; Richter A; Vordermark D; Flentje M
Radiat Oncol; 2008 Jan; 3():3. PubMed ID: 18190681
[TBL] [Abstract][Full Text] [Related]
15. Internal fiducial markers can assist dose escalation in treatment of prostate cancer: result of organ motion simulations.
Zhang M; Moiseenko V; Liu M; Craig T
Phys Med Biol; 2006 Jan; 51(2):269-85. PubMed ID: 16394338
[TBL] [Abstract][Full Text] [Related]
16. The sensitivity of dose distributions for organ motion and set-up uncertainties in prostate IMRT.
Bos LJ; van der Geer J; van Herk M; Mijnheer BJ; Lebesque JV; Damen EM
Radiother Oncol; 2005 Jul; 76(1):18-26. PubMed ID: 16024120
[TBL] [Abstract][Full Text] [Related]
17. Determination of optimal PTV margin for patients receiving CBCT-guided prostate IMRT: comparative analysis based on CBCT dose calculation with four different margins.
Gill SK; Reddy K; Campbell N; Chen C; Pearson D
J Appl Clin Med Phys; 2015 Nov; 16(6):252–262. PubMed ID: 26699581
[TBL] [Abstract][Full Text] [Related]
18. A phase II trial for the optimisation of treatment position in the radiation therapy of prostate cancer.
O'Neill L; Armstrong J; Buckney S; Assiri M; Cannon M; Holmberg O
Radiother Oncol; 2008 Jul; 88(1):61-6. PubMed ID: 18453021
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric effects of patient rotational setup errors on prostate IMRT treatments.
Fu W; Yang Y; Li X; Heron DE; Huq MS; Yue NJ
Phys Med Biol; 2006 Oct; 51(20):5321-31. PubMed ID: 17019041
[TBL] [Abstract][Full Text] [Related]
20. Dosimetric effects of the prone and supine positions on image guided localized prostate cancer radiotherapy.
Liu B; Lerma FA; Patel S; Amin P; Feng Y; Yi BY; Yu C
Radiother Oncol; 2008 Jul; 88(1):67-76. PubMed ID: 18207595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
